Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Entrada Therapeutics Inc (TRDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TRDA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18.5
1 Year Target Price $18.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -75.85% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 199.69M USD | Price to earnings Ratio - | 1Y Target Price 18.5 |
Price to earnings Ratio - | 1Y Target Price 18.5 | ||
Volume (30-day avg) 4 | Beta -0.13 | 52 Weeks Range 4.93 - 21.79 | Updated Date 08/15/2025 |
52 Weeks Range 4.93 - 21.79 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.82 | Actual -1.04 |
Profitability
Profit Margin -92.3% | Operating Margin (TTM) -2402.51% |
Management Effectiveness
Return on Assets (TTM) -11.66% | Return on Equity (TTM) -18.13% |
Valuation
Trailing PE - | Forward PE 3333.33 | Enterprise Value -99574336 | Price to Sales(TTM) 2.51 |
Enterprise Value -99574336 | Price to Sales(TTM) 2.51 | ||
Enterprise Value to Revenue 0.64 | Enterprise Value to EBITDA 1.58 | Shares Outstanding 38037100 | Shares Floating 19098027 |
Shares Outstanding 38037100 | Shares Floating 19098027 | ||
Percent Insiders 12.33 | Percent Institutions 80.79 |
Upturn AI SWOT
Entrada Therapeutics Inc
Company Overview
History and Background
Entrada Therapeutics Inc. is a biopharmaceutical company focused on developing and delivering intracellular therapeutics to treat diseases that have been historically inaccessible. Founded in 2016, they are pioneering Endosomal Escape Vehicle (EEV) therapeutics to address significant unmet needs.
Core Business Areas
- EEV Therapeutics Development: Entrada's core business revolves around developing EEV therapeutics, designed to deliver therapeutic payloads directly into cells. These payloads include proteins, oligonucleotides, and small molecules.
- Neuromuscular Disease Programs: A key focus area includes developing therapies for neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD).
- Other Disease Targets: Entrada is also exploring the application of its EEV platform to other disease areas, including immunology and oncology.
Leadership and Structure
The leadership team consists of experienced biotech executives and scientists. The organizational structure is typical of a clinical-stage biotech company, with departments focused on research, development, clinical trials, and corporate functions.
Top Products and Market Share
Key Offerings
- ENTR-601-44 (DMD Program): ENTR-601-44 is Entrada's lead program, designed to treat Duchenne Muscular Dystrophy (DMD) by delivering exon-skipping oligonucleotides into muscle cells. Market share data is not yet available as the product is in clinical development. Competitors include Sarepta Therapeutics (SRPT) and Vertex Pharmaceuticals (VRTX).
- EEV Platform Technology: Entrada's proprietary EEV platform is a key offering, enabling the delivery of various therapeutic payloads into cells. This platform has the potential to generate multiple therapeutic candidates. Competitors are companies with other intracellular delivery technologies, however none can claim similar efficacy and safety in their target indications.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. There is growing demand for novel therapeutics, particularly for diseases with unmet medical needs.
Positioning
Entrada is positioned as an innovator in intracellular therapeutics, leveraging its EEV platform to address previously undruggable targets. Its competitive advantage lies in its proprietary delivery technology.
Total Addressable Market (TAM)
The TAM for Duchenne Muscular Dystrophy and other diseases targeted by Entrada's EEV platform is estimated to be billions of dollars. Entrada is positioned to capture a significant portion of this market if its therapies are successful.
Upturn SWOT Analysis
Strengths
- Proprietary EEV delivery platform
- Strong preclinical and clinical data
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Reliance on a single technology platform
- High cash burn rate
- Clinical trial risks
- Limited commercialization experience
Opportunities
- Expansion of EEV platform to new therapeutic areas
- Strategic partnerships and collaborations
- Positive clinical trial results
- Potential for breakthrough therapy designation
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- SRPT
- VRTX
- BMY
Competitive Landscape
Entrada faces competition from established pharmaceutical companies with existing therapies for neuromuscular diseases. Its competitive advantage lies in its innovative EEV delivery platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and clinical development of its EEV platform and pipeline programs.
Future Projections: Future growth depends on the success of clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing ENTR-601-44 into later-stage clinical trials and expanding the EEV platform to new targets.
Summary
Entrada Therapeutics is a clinical-stage biopharmaceutical company innovating intracellular therapeutics, particularly for Duchenne Muscular Dystrophy. Their proprietary EEV platform shows promise, but the company faces clinical trial risks and competition. Successful clinical trials and strategic partnerships are crucial for its future growth, as financial stability remains a key concern. Entrada's future success depends on demonstrating the efficacy and safety of its technology.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Entrada Therapeutics Inc. website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data and projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Entrada Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-10-29 | CEO & Director Mr. Dipal Doshi | ||
Sector Healthcare | Industry Biotechnology | Full time employees 183 | Website https://www.entradatx.com |
Full time employees 183 | Website https://www.entradatx.com | ||
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45, ENTR-601-50, and ENTR-601-51, which are in preclinical trial, for the treatment of Duchenne muscular dystrophy; and PTI-501, an intracellular thymidine phosphorylase enzyme replacement therapy for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. It has strategic collaboration and license agreements with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize VX-670; and Pierrepont Therapeutics, Inc. to advance the development of PTI-501. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.